A novel business model, brand value and global presence have
accelerated the growth of Invitrogen
Invitrogen Bioservices India
Devashish Ohri (MD)
Life Sciences Business
Manufacturer and supplier of biotech consumables and instruments
First Technology Place, 3 EPIP, Whitefield, Bangalore-560066, Karnataka
(in Rs Crore)
Rs 150* Crore
* BioSpectrum estimates
Millipore's products are backed with service support through the
company's extensive network of sales offices in India
Life Technologies Corporation, the US-based parent company of Invitrogen Bioservices India, operates as
a global biotech tools company focused on improving human health. With more than 50,000 products used
by more than 75,000 customers around the globe, and with revenues clocking Rs 15,387 cr ($3.3 bn)
globally, Life Technologies is advancing scientific research in the areas of academic research,
drug discovery and development, toxicology and forensics, disease diagnostics, clinical cell therapy,
regenerative medicine and biologics manufacturing.
Life Technologies' Indian arm Invitrogen Bioservices India specializes in biotech consumables and
benchtop instruments. In 2005, Invitrogen commenced its India operations.
According to BioSpectrum
estimates, Invitrogen is estimated to have registered life sciences
sales revenue of Rs 150 crore in FY 2009-10 as against Rs 120 crore in FY 2008-09 from its India
operations. Invitrogen is currently operating from its integrated state-of-the-art facility in
Bangalore. Through its products and services, the company enables its customers to gain insight
into a spectrum of scientific activities.
The company's renowned brands include GIBCO (media, reagents, cells, and sera serum for cell
culture), SuperScript (RT gene expression, cDNA synthesis), Lipofectamine (transfection reagents),
Trizol and Trizol Plus (RNA purification system); TOPO (PCR cloning) and Benchtop instruments.
A customer-centric business model coupled with reliable and innovative brand value, strategic
leadership, strong service delivery, dedicated workforce and global presence has accelerated
the growth of Invitrogen.
Devashish Ohri, managing director of Invitrogen's South Asia operations, says, “These are
exciting times for biotech sector in India because of the huge chunk of innovation drugs going
off-patent and the consequent rapid ramp up by key Indian biosimilar manufacturers. The government
and private research laboratories have also become more aggressive in their innovation strategy.”
He opines that the next wave of growth will come from applied markets related to biofuels,
diagnostics, forensics and agriculture.